BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Biolinq Shine just became the first needle-free glucose sensor Americans can buy without a prescription, after the FDA granted 510(k) clearance for over-the-counter use on September 24.
What happened
San Diego-based Biolinq announced that the FDA cleared Biolinq Shine for OTC use, following the De Novo classification the device received in September 2025. Shine is a forearm patch that combines glucose, activity, and sleep tracking in a single wearable — and it is the first glucose sensor with an integrated primary display that works with or without a phone. A color-coded LED signals whether glucose is in, above, or below target range in real time.
Key figures:
– 510(k) OTC clearance granted September 24, 2026
– De Novo classification: September 2025
– Microsensor array up to 20x shallower than conventional CGM needles
– No subcutaneous introducer needle required
– $100M Series C funding raised last year
– Initially targeted at people with type 2 diabetes not on insulinWhy it matters
The OTC switch expands the addressable market well beyond prescription CGM users. Conventional continuous glucose monitors require a needle-inserted filament and a prescription; removing both barriers opens the product to the much larger prediabetes and lifestyle-metabolic crowd. That puts Shine in direct conceptual competition with Dexcom, Abbott, and Medtronic’s diabetes franchises, which have long dominated glucose sensing — and it pressures them to accelerate their own OTC or needle-free roadmaps.
The device’s semiconductor-manufactured microsensor array also hints at a platform: Biolinq says multi-analyte sensing could follow in future generations, potentially moving the wearable beyond glucose into broader metabolic monitoring.
What to watch
Pricing and launch timing will decide whether this is a niche product or a category shift. Watch for retail distribution deals, any response from Abbott or Dexcom on OTC positioning, and real-world adherence data — needle-free means little if users do not keep the patch on.
Related reading: Eli Lilly’s Onswik — a once-weekly insulin that won FDA approval earlier this month: https://bullounge.com/forums/topic/eli-lilly-wins-fda-approval-for-onswik-its-once-weekly-insulin-for-type-2-diabetes/
Would you ditch a needle-inserted CGM for a needle-free patch, or do you trust the incumbents’ accuracy track record more?
Auto-posted by the Bull Lounge news desk. Not financial advice.
Log in to vote
